Literature DB >> 6729450

T and Tn, general carcinoma autoantigens.

G F Springer.   

Abstract

Primary and metastatic carcinomas are epithelial in origin and comprise by far the largest group of malignant tumors in humans. In most of these tumors, T and Tn antigens, whose epitopes have been synthesized, are uncovered and immunoreactive. In all other tissues T and Tn antigens are masked and not accessible to the immune system; they are generally precursors in normal complex carbohydrate chains. Thus, carcinomas have antigens recognized as foreign by the patients' immune system. The expression of T and Tn antigens has pathogenic and clinical consequences, and the antigens themselves are powerful histological markers in carcinoma diagnosis and frequently in prognosis. Most patients distinguish their carcinoma from all other cells, as shown by strong autoimmune responses to T antigen. These responses are readily measured by assays, and they allow detection of carcinomas with greater sensitivity and specificity frequently earlier than previously possible. Moreover, the extent of T and Tn expression often correlates with carcinoma differentiation; on a molecular level, clustered T- and Tn-active structures on carcinoma cell surfaces may be involved in invasion.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6729450     DOI: 10.1126/science.6729450

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  217 in total

Review 1.  The glycosynapse.

Authors:  Sen-itiroh Hakomori Si
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-02       Impact factor: 11.205

Review 2.  The chemistry and immunochemistry of blood group A, B, H, and Lewis antigens: past, present and future.

Authors:  K O Lloyd
Journal:  Glycoconj J       Date:  2000 Jul-Sep       Impact factor: 2.916

3.  Carbohydrate antigen delivery by water soluble copolymers as potential anti-cancer vaccines.

Authors:  Qian Qin; Zhaojun Yin; Philip Bentley; Xuefei Huang
Journal:  Medchemcomm       Date:  2014-08-01       Impact factor: 3.597

4.  Correlation between the sialylation of cell surface Thomsen-Friedenreich antigen and the metastatic potential of colon carcinoma cells in a mouse model.

Authors:  Y Nemoto-Sasaki; M Mitsuki; M Morimoto-Tomita; A Maeda; M Tsuiji; T Irimura
Journal:  Glycoconj J       Date:  2001 Nov-Dec       Impact factor: 2.916

Review 5.  [Tumor lectinology--status and perspectives of clinical application].

Authors:  H J Gabius; S Gabius
Journal:  Naturwissenschaften       Date:  1990-11

6.  Antibody-dependent cell cytotoxicity in monoclonal antibody-mediated tumor immunotherapy.

Authors:  Pascale Hubert; Sebastian Amigorena
Journal:  Oncoimmunology       Date:  2012-01-01       Impact factor: 8.110

7.  Epigenetic silencing of the chaperone Cosmc in human leukocytes expressing tn antigen.

Authors:  Rongjuan Mi; Lina Song; Yingchun Wang; Xiaokun Ding; Junwei Zeng; Sylvain Lehoux; Rajindra P Aryal; Jianmei Wang; Vanja K Crew; Irma van Die; Arlene B Chapman; Richard D Cummings; Tongzhong Ju
Journal:  J Biol Chem       Date:  2012-10-03       Impact factor: 5.157

8.  Structural and immunocytochemical studies on alpha-N-acetylgalactosaminidase deficiency (Schindler/Kanzaki disease).

Authors:  Hitoshi Sakuraba; Fumiko Matsuzawa; Sei-Ichi Aikawa; Hirofumi Doi; Masaharu Kotani; Hiroshi Nakada; Tomoko Fukushige; Tamotsu Kanzaki
Journal:  J Hum Genet       Date:  2003-12-19       Impact factor: 3.172

9.  A novel synthetic bipartite carrier protein for developing glycotope-based vaccines.

Authors:  Hsiao-Ling Chiang; Chi-Yu Lin; Fan-Dan Jan; Yaoh-Shiang Lin; Chia-Tse Hsu; Jacqueline Whang-Peng; Leroy F Liu; Shin Nieh; Chun-Cheng Lin; Jaulang Hwang
Journal:  Vaccine       Date:  2012-10-22       Impact factor: 3.641

10.  Epitopic structure of Tn glycophorin A for an anti-Tn antibody (MLS 128).

Authors:  H Nakada; M Inoue; Y Numata; N Tanaka; I Funakoshi; S Fukui; A Mellors; I Yamashina
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.